JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

A

147.08

+0.55%↑

JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

A

147.08

+0.55%↑

JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

A

147.08

+0.55%↑

JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

A

147.08

+0.55%↑

JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

A

147.08

+0.55%↑

Search

Alkermes PLC

Atidarymo kaina

SektoriusSveikatos priežiūra

30.23 -3.26

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

29.88

Max

31.32

Pagrindiniai rodikliai

By Trading Economics

Pajamos

65M

87M

Pardavimai

84M

391M

P/E

Sektoriaus vid.

14.613

37.461

Pelno marža

22.295

Darbuotojai

1,800

EBITDA

99M

113M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+29.09% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-10-28

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

802M

5.1B

Ankstesnė atidarymo kaina

33.49

Ankstesnė uždarymo kaina

30.23

Naujienos nuotaikos

By Acuity

50%

50%

168 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Alkermes PLC Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-22 22:47; UTC

Įsigijimai, susijungimai, perėmimai

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

2025-10-22 22:13; UTC

Įsigijimai, susijungimai, perėmimai

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

2025-10-22 21:20; UTC

Uždarbis

Correction to IBM 3Q Sales Jump Article

2025-10-22 20:57; UTC

Uždarbis

SAP Posts Higher 3Q Revenue, Operating Profit

2025-10-22 23:46; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-22 23:46; UTC

Rinkos pokalbiai

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

2025-10-22 23:41; UTC

Rinkos pokalbiai

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

2025-10-22 23:38; UTC

Rinkos pokalbiai

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

2025-10-22 23:15; UTC

Uždarbis

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

2025-10-22 22:28; UTC

Rinkos pokalbiai

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

2025-10-22 22:02; UTC

Uždarbis

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

2025-10-22 21:59; UTC

Įsigijimai, susijungimai, perėmimai

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

2025-10-22 21:58; UTC

Įsigijimai, susijungimai, perėmimai

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

2025-10-22 21:57; UTC

Įsigijimai, susijungimai, perėmimai

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

2025-10-22 21:56; UTC

Įsigijimai, susijungimai, perėmimai

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

2025-10-22 21:47; UTC

Įsigijimai, susijungimai, perėmimai

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

2025-10-22 21:47; UTC

Uždarbis

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

2025-10-22 21:47; UTC

Įsigijimai, susijungimai, perėmimai

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

2025-10-22 21:46; UTC

Įsigijimai, susijungimai, perėmimai

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

2025-10-22 21:45; UTC

Įsigijimai, susijungimai, perėmimai

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

2025-10-22 21:45; UTC

Įsigijimai, susijungimai, perėmimai

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

2025-10-22 21:28; UTC

Rinkos pokalbiai
Uždarbis

Correction to Alcoa Tariff Market Talk

2025-10-22 21:25; UTC

Uždarbis

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

2025-10-22 21:17; UTC

Uždarbis

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

2025-10-22 21:09; UTC

Rinkos pokalbiai
Uždarbis

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

2025-10-22 21:00; UTC

Rinkos pokalbiai

ESG Roundup: Market Talk

2025-10-22 20:59; UTC

Uždarbis

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

2025-10-22 20:51; UTC

Uždarbis

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

2025-10-22 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-22 20:44; UTC

Uždarbis

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Akcijų palyginimas

Kainos pokytis

Alkermes PLC Prognozė

Kainos tikslas

By TipRanks

29.09% į viršų

12 mėnesių prognozė

Vidutinis 40.6 USD  29.09%

Aukščiausias 47 USD

Žemiausias 33 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Alkermes PLC kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

11 ratings

7

Pirkti

4

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

27.95 / 30.91Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

168 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
help-icon Live chat